Redefining access to innovative oncology therapies: Can managed entry agreements help?

Redefining access to innovative oncology therapies: Can managed entry agreements help?

Tim Wilsdon
Life Sciences

At the ISPOR Warsaw 2019 regional conference, a panel examined country experiences with managed entry agreements and their impact on improving access to innovative oncology therapies.

This article summarizes the lessons learned from implementing managed entry and multi-year, multi-indication agreements in different regional contexts.

Download PDF